Biotech Values

[DewDiligence]

Teva’s ‘low-volume’ Copaxone will almost certainly not be brought to market. The subject came up at Teva’s NY luncheon for analysts yesterday and Bill Marth’s reply was that “the future of the program is being debated inside Teva” and that it’s unclear whether the prospects warrant conducting the large safety and efficacy study the FDA demanded as a condition for approval. This is biotech-speak for saying that the program is dead.